Paratek pharmaceuticals, inc. (PRTK)
Income statement / Yearly
Dec'19Dec'18Dec'17Dec'16Dec'15Dec'14Dec'13Dec'12Dec'11Dec'10Dec'09
Net revenue

16,544

17,117

12,616

-

-

-

-

-

-

-

-

Collaboration and royalty revenue

-

-

-

29

-

-

-

-

-

-

-

Research and development collaborations

-

-

-

-

-

4,342

478

-

-

-

-

Royalty Revenue

-

-

-

-

0

0

-

776

0

0

-

Total revenue

-

-

-

29

-

4,342

-

-

-

-

-

Gross license fee revenue

-

-

-

-

-

-

-

0

7,292

12,500

5,208

Gross milestone revenue

-

-

-

-

-

-

-

10,000

10,000

-

-

Gross milestone revenue

-

-

-

-

-

-

-

-

-

0

-

Other Revenue, Net

-

-

-

-

-

-

-

250

2,402

0

-

Advertising expense - Purdue Pharma

-

-

-

-

-

-

-

1,429

0

0

-

Net revenue

-

-

-

-

-

-

-

9,597

19,694

12,500

5,208

Expenses:
Cost of product revenue

3,484

-

-

-

-

-

-

-

-

-

-

Research and development

39,554

57,508

60,072

83,460

50,765

5,014

4,631

11,191

11,273

10,684

9,005

Selling, general and administrative

89,135

63,658

-

-

-

-

-

-

-

-

-

General and administrative

-

-

36,965

26,400

19,988

5,848

3,387

10,263

12,185

11,038

16,050

Impairment of intangible assets

-

107

743

-

2,860

0

0

-

-

-

-

Merger-related costs

-

-

-

-

-

1,278

-

-

-

-

2,224

Changes in fair value of contingent consideration

-

-71

-584

-345

-3,560

-

-

-

-

-

-

Goodwill impairment

-

-

-

-

-

-

-

0

0

-

-

Total operating expenses

132,173

121,202

97,196

109,515

70,053

12,140

8,018

21,454

23,458

21,722

27,279

Loss from operations

-115,629

-104,085

-84,580

-109,486

-70,053

-7,798

-7,540

-11,857

-3,764

-9,222

-22,071

Other income and expenses:
Interest income

3,574

3,260

1,377

1,069

-

-

-

-

-

-

282

Interest expense

16,403

10,985

5,079

3,223

770

718

-

-

-

-

179

Other losses, net

31

44

-

-

-

-

-

-

-

-

-

Interest expense, net

-

-

-

-

-

-

-294

-

-

-

-

Loss on exchange of non-convertible notes for common stock

-

-

-

-

-

-9,020

-

-

-

-

-

(Loss) gain on mark-to-market of notes and warrants

-

-

-

-

-

-120

8,051

-

-

-

-

Other gains (losses), net

-

-

-34

4

-37

-179

-

-159

-116

-81

168

Net loss before provision for income taxes

-128,489

-111,854

-88,316

-111,636

-

-

-

-

-

-

-

Provision for income taxes

301

502

753

-

-

-

-

-

-

-

-

Loss on issuance of convertible notes

-

-

-

-

-

-

-2,040

-

-

-

-

Loss on issuance of equity associated with convertible notes

-

-

-

-

-

-

-2,948

-

-

-

-

Other loss, net

-

-

-

-

-

-

118

-

-

-

-

Net loss

-128,790

-112,356

-89,069

-111,636

-70,860

-17,835

-4,653

-12,016

-3,880

-9,303

-21,800

Unaccreted dividends on convertible preferred stock

-

-

-

-

-

1,927

6,766

-

-

-

-

Net loss attributable to common stockholders

-

-

-

-

-70,860

-19,762

-11,419

-

-

-

-

Other comprehensive loss
Unrealized gain on available-for-sale securities, net of tax

202

30

-142

-16

-

-

-

-22

27

-37

-

Other comprehensive gain

202

30

-142

-16

-

-

-

-

-

-

-

Weighted average shares outstanding

-

-

-

-

-

-

-

-

-

-

12,166

Comprehensive loss

-128,588

-112,326

-89,211

-111,652

-70,860

-19,762

-

-12,038

-3,853

-9,340

-

Net loss per share:
Basic and diluted net loss per common share

-3.93

-3.57

-3.32

-5.51

-4.29

-7.82

-185.13

-0.70

-0.29

-0.69

-1.79

Weighted average common stock outstanding Basic and diluted

32,791

31,513

26,827

20,253

16,501

2,528

61

17,052

13,534

13,416

-

Product Revenue, Net [Member]
Net revenue

11,517

-

-

-

-

-

-

-

-

-

-

Collaboration and Royalty Revenue [Member]
Net revenue

5,027

17,117

-

-

-

-

-

-

-

-

-